Unlocking the Next Signal in Precision Oncology: RNA Liquid Biopsy for Early Detection & Drug Development
4:45 pm - Thursday 18th March 2027
- Discovering novel cell-free RNA biomarkers through longread nanopore sequencing and machine learning to expand opportunities for early cancer and precancer detection
- Revealing dynamic tumor and host biology beyond genomic alterations to inform patient stratification, therapeutic response monitoring, and oncology drug development
- Integrating cell-free RNA with ctDNA, AI, and multimodal clinical data to advance next-generation liquid biopsy platforms for precision oncology
